Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03502941 · ClinicalTrials.gov registry record · NA
Effect of an EAA/Whey Composition on Protein Metabolism
A NA study, sponsored by University of Arkansas.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT03502941: Completed NA study, sponsored by University of Arkansas.
NCT03502941 is a NA study that has completed, run by University of Arkansas. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03502941, a NA study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
Sarcopenia, a progressive loss of muscle mass, strength and function, is an inevitable natural process of aging. While it may be impossible to completely reverse the progress of sarcopenia, it is well established that intake of dietary protein through essential amino acids (EAAs) and whey protein increases anabolic response. The current study will test if a specially formulated mixture of EAAs and whey protein can maximally stimulate anabolic responses at the levels of whole body and muscle compared to whey protein alone.
Primary Outcome
Changes in net protein balance at whole body (grams)
Interventions
- DIETARY_SUPPLEMENT 6.3 g of EAAs mixture and whey protein isolate
- DIETARY_SUPPLEMENT 12.6 g of EAAs mixture and whey protein isolate
- DIETARY_SUPPLEMENT 12.6 g of whey protein isolate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-06-20 |
| Est. Completion | 2019-07-17 |
| Phase | NA |
What the finished NCT03502941 record still lists
NCT03502941 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which 6.3 g of EAAs mixture and whey protein isolate is the first listed.
NCT03502941 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03502941 about?
NCT03502941 is a clinical study titled "Effect of an EAA/Whey Composition on Protein Metabolism". Sarcopenia, a progressive loss of muscle mass, strength and function, is an inevitable natural process of aging. While it may be impossible to completely reverse the progress of sarcopenia, it is well established that intake of dietary protein through essential amino acids (EAAs) and whey protein in...
What is the current status of trial NCT03502941?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2018-06-20. Estimated completion is 2019-07-17.
What interventions are being tested in trial NCT03502941?
The interventions under investigation include: 6.3 g of EAAs mixture and whey protein isolate (DIETARY_SUPPLEMENT), 12.6 g of EAAs mixture and whey protein isolate (DIETARY_SUPPLEMENT), 12.6 g of whey protein isolate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03502941?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03502941's enrollment target sits among peer trials
16 1871st of 2000 higher than 120 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI